JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights.

LOS ANGELES — A wearable, behind-the-ear EEG device is feasible for assessment of sleep patterns in young people with Dravet syndrome, according to a poster presented at the American Epilepsy ...

LOS ANGELES — A wearable, behind-the-ear EEG device is feasible for assessment of sleep patterns in young people with Dravet syndrome, according to a poster presented at the American Epilepsy ...

Novo Nordisk's stock plunges 20% after underwhelming weight-loss trial results for its obesity drug. Analysts say market overreacted.

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

I had been taking Zepbound for about six months when it clicked. My period — the monster that turned me from a functioning ...

Scaling Obesity and CV-Met For the new obesity therapeutics making waves, 2023 was a year of major approvals, with the launch of Zepbound ... of Chat GPT3 became the poster child for mass adoption ...

The U.S. Food and Drug Administration (FDA) recently approved Zepbound® (tirzepatide) as the first prescription medication for treating moderate-to-severe obstructive sleep apnea (OSA ...

Shelby Knowles / Bloomberg via Getty Images Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for sleep apnea last month. Weight loss ...

Eli Lilly and Company LLY announced that the FDA has approved its popular obesity drug, Zepbound (tirzepatide) for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity.